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Large clinical trials beginning with the PACTG-076 trial and other trials across Europe and 
America have showed that perinatal exposure to Zidovu ine (AZT) results in 
haematological side effects in the neonate, mainly anaemia, which are clinically 
insignificant and reversible. There is however limited data in sub-Saharan Africa on the 
impact of intrauterine exposure to AZT on neonates, particularly low birth weight neonates, 
at the height of the HIV/PMTCT era. 
 
The aim of the study was to evaluate the prevalence a d clinical significance of anaemia 
among low birth weight neonates, in a diverse South African setting. This observational 
descriptive study looked at medical records of HIV-exposed, low-birth weight neonates 
(less than 2500g) admitted to the neonatal unit at King Edward VIII Hospital from May 
2008 to February 2010, who have had intrauterine exposure to AZT.  
 
A total of 95 neonatal birth and medical records were analysed. The total prevalence of 
anaemia was 47%.  The neonates were placed into categories according to gestational age. 
The prevalence of anaemia was 16.7% and the mean Hb was 17g/dL in the 26-28 week 
gestational age category, prevalence of anaemia was 37% and mean Hb was 16g/dL in the 
29-31 week category, and the prevalence of anaemia was 54.8% with a mean of 17g/dL in 
the over 31 week gestational age category. The minimum haemoglobin was 11.0g/dL and 
maximum haemoglobin was 24g/dL. The mean haemoglobin in the neonates exposed to 
more than 28 days of Zidovudine was lower than the mean Hb in neonates exposed to less 
than 28 days in the 29-31week and over 31 week gestational age categories. 
 
The haematological side effects of anaemia in neonat s resulting from AZT exposure in-
utero were found to be prevalent but of a mild and clinically insignificant nature in keeping 
with existing international and continental studies. The severity of anaemia in low birth 
weight/ pre-term neonates appears to be the same as in term neonates of normal birth 
weight depicted in these studies. The presence of nonatal anaemia at birth has been shown 
to be related to the duration of exposure to intrauterine AZT in one of the three age roups. 
 
There were no identified issues that would warrant amending current recommendations for 
the routine use of AZT for the prevention of mother-child HIV transmission however these 
findings require further research involving larger numbers and follow up of neonates in 
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HIV Human Immunodeficieny Virus 
LBW Low birth weight 
MTCT Maternal to child transmission 
NVP Nevirapine 
PACT-076 Paediatric AIDS Clinical Trial 
PMTCT Prevention of mother to child transmission 
TDF Tenofovir 
      
Definitions 1  
 
HIV-exposed neonate: 
A newborn baby born to a HIV-positive woman. 
 
Infant: 
A person from birth to 12 months of age.  
 
Low birth weight neonate: 
A newborn baby weighing < 2500g. 
 
Mother-to-child transmission 
Transmission of HIV from a HIV-positive woman to her baby during pregnancy, 
delivery, or breastfeeding. 
 
Neonate 
A newborn baby in the first 28 days after birth.   
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Aim 
The aim of this study was to determine the prevalence and degree of anaemia in HIV-
exposed low birth weight neonates (< 2500g), admitted to the neonatal unit in King 
Edward VIII Hospital from April 2008 until February 2010, who were exposed to 
intrauterine Zidovudine (AZT). 
Introduction  
With the exception of a small number of African studies and predominantly first world 
studies on the effects of AZT on neonates at the height of the HIV/PMTCT era, there is 
limited research in sub-Saharan Africa on babies with neonatal anaemia who have had 
intrauterine exposure to AZT to determine whether t anaemia is clinically significant or 
not. The PROMISE IMPAACT study2 is currently being conducted in many resource-
limited countries including South Africa and a secondary objective of the study is to 
document side effects of Prevention of Mother to Child Transmission (PMTCT) 
medication on mother and baby. It was necessary to closely evaluate the prevalence and 
clinical significance of anaemia in a diverse South African setting. Furthermore, most 
studies have excluded low birth weight neonates because anaemia can result from 
prematurity and it may be difficult to determine whet er anaemia is due to prematurity or 
to AZT exposure. Hence it was worthwhile to evaluate data in this vulnerable group. 
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Literature review 
 
As a background to the study it is valuable to present information on the following:   
 
1. An introduction to the prevalence of HIV in babies n South Africa 
2. The evolution of and the on going need for an improving PMTCT programme in 
South Africa 
3. What is zidovudine (AZT)? 
4. Anaemia, a common side effect of zidovudine 
5. The definition and causes of neonatal anaemia 
 
An introduction to the prevalence of HIV in babies in South Africa 
 
At the 2009 maternal, child and women's health summit presented by the National 
Minister of Health Dr Aaron Motsoaledi, it was stated that in South Africa greater than 1 
million babies are born annually of whom 300 000 were HIV-exposed based on the 
prevalence of HIV in pregnant women in 2007. An estimated 22000 neonates die every 
year in South Africa and up to 43% of these were probably avoidable as many of these 
deaths could possibly have been attributed to HIV(The National Perinatal and Neonatal 
Morbidity and Mortality Committee 2008). At the summit it was also highlighted that 
50% of the annual deaths of children in South Africa between birth and five years have 
HIV as the underlying cause (The Committee on Morbidity and Mortality in Children 




Dr S Hanley MMed Thesis 
The evolution of and the on going need for an improving PMTCT 
programme in South Africa 
 




After the PACTG 076 trial in 19984, the 6-week neonatal AZT prophylaxis became the 
benchmark of Prevention of Mother to Child Transmission (PMTCT) in most first world 
countries. The PMTCT programme in South Africa dates back to 1999 to a district called 
Khayelitsha in the province of the Western Cape where PMTCT utilising AZT at 34 
weeks gestation and at birth was initiated. In 2004 the entire province commenced AZT 
in pregnant women from 28 weeks of gestation as well as single dose Nevirapine (NVP) 
at the onset of labour. By this time the rest of South Africa had initiated a national 
PMTCT policy comprising of just a single dose NVP given at the onset of labour.5 A 
large clinical trial in Thailand in 2005 demonstrated a 2% transmission of the HI virus 
from mother to child when utilising AZT from 28 weeks gestation and single dose NVP 
at the onset of labour.6 The baby received single dose NVP at delivery and 1 week of 
AZT. This landmark study led to the introduction of dual therapy (AZT and NVP) taken 
by pregnant women as well as AZT prophylaxis in their babies in South Africa in 2008.  
 
As of April 2010 a revised PMTCT programme was launched in South Africa advocating 
AZT from 14 weeks gestation in all women with CD4 counts more than 350cells/mm3. In 
addition to the AZT the mother receives single dose TDF and FTC at delivery. The baby 
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must be given 6 weeks of NVP or for the duration of breast feeding, and no AZT. Other 
key components of the new policy include HIV testing of every pregnant woman, treating 
all pregnant HIV-positive women with ARVs if the CD4 is less than 350 and follow up 
all mothers and infants at 6 weeks post-partum. Currently mother to child transmission 
(MTCT) rates vary widely across the country, averaging at 12% nationally1, highlighting 
the need for a constantly improving PMTCT programme. 
The administration of triple ARV drug combinations, delivery via caesarean section, and 
infant formula-feeding have resulted in a significant decrease in the risk of MTCT in the 
US, Europe and other first world countries. However in esource limited settings, HIV-
infected mothers and their babies are prone to anaemia ven when not on ARV therapy 
and most mothers choose to breast feed. 
What is zidovudine (AZT)? 
Azido-deoxythymidine known as AZT is the most widely used ARV in pregnancy as part 
of the PMTCT programme. It is a nucleoside analogue rev rse transcriptase inhibitor and 
was the first ARV approved by the United States Food and Drug Administration. 
Zidovudine and the other ARVs reduce MTCT by decreasing viral replication thereby 
reducing the maternal viral load. In this way AZT provides pre-exposure prophylaxis to 
the baby preventing cross-placental and intra-partum ransmission and post-exposure 
prophylaxis by administering the ARV to the baby after delivery.7  
Anaemia, a common side effect of zidovudine 
Anaemia is a well known side effect of AZT which was demonstrated in a meta-analysis 
of 6 RCT published in 2004, one of many related studies.8 The in vitro inhibitory effect 
of AZT on haematopoietic progenitors was described in a study by Dainiak in 1988.9 
Large clinical trials and cohort studies beginning with the PACTG-076 study10 and other 
studies across Europe and the US have shown that perinatal exposure to AZT results in 
haematological side effects mainly anaemia which is clinically insignificant and 
reversible. Studies have shown that due to maternal int ke of AZT during gestation, 
anaemia is present in neonates from birth to 2 weeks of age. If the neonates are taking 
6 
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AZT prophylaxis the resolution of anaemia is slowed down by a longer duration of AZT 
as well as in the HIV infected neonates. In most neonates the haemoglobin levels returned 
to normal by 2-3 months after cessation of AZT.11,12 A Tanzanian study demonstrated  
that AZT exposure in-utero can cause mild and transient haematologic alterations in 
infants.13 Two studies in Malawi explored haematological changes in African children 
who received either NVP or AZT at birth and concluded that age specific anaemia was 
the same in the two groups and showed no long term haematological adverse effects.14,15 
With the exception of these African studies few comparable studies have been carried out 
in the rest of Africa, and in particular in sub-Saharan Africa. 
 
The definition and causes of neonatal anaemia.  
Anaemia is defined as haemoglobin or haematocrit concentration of more than two 
standard deviations below the mean for age.16  
The average haemoglobin values on the first postnatal d y for the gestational age of 26-
28 week gestation is 15.1g/dL, gestational age of 28-31 weeks is 16.2g/dL and gestational 
age of more than 31 weeks is 19.3g/dL.16 A 26 – 28 week gestation baby would be 
considered to be anaemic if the Hb was less than 13.5g/dL, a 28 – 31 week gestation baby 
would be considered to be anaemic if the HB was les than 14.5g/dL and a baby with a 
gestational age of more than 31 weeks could be considered anaemic if the HB was less 
than 17.1g/dL. 
 
There are multiple factors contributing to anaemia in newborns apart from AZT which 
affects foetal and infant erythroid lineages in the bone marrow. 
The common causes are: 17,18 
 
- Loss of blood : antepartum haemorrhage and blood loss during traumatic delivery, 
early umbilical cord clamping, occult bleeding for example twin-twin and foetal-
placental transfusion when the neonate is held above the placenta for some time 
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after delivery, recurrent excess phlebotomy especially for close monitoring of 
preterm infants 
- Decrease in production of red blood cells: congenital causes for example Fanconi 
anaemia, anaemia of prematurity, and Diamond-Blackfan anaemia; acquired 
causes such as infection including HIV, parvovirus and syphilis, nutritional 
deficiencies especially in premature babies due to rapid growth, perinatal drug 
exposure as in the case of AZT  
- Increase in destruction: shortened red blood cell life span. In the extreme 
premature infants cells survive only up to 50 days. The shortened red blood cell 
life span of the neonate is a result of multiple factors for example infection 
including HIV, haemolytic disease of the newborn, haemoglobinopathies,  and 
enzymopathies 
Anaemia is said to be clinically significant and severe if the HB is less than 10g/dL 
during the first few days of life (Grade 3, Grade 4 Division of AIDS toxicity levels).19 
The lowest haemoglobin levels following birth are typically observed when the smallest 
infants are aged 4-10 weeks, with concentrations of 8-10 g/dL if birth weight was 1200-
1400 grams or 6-9 g/dL if birth weight was less than 1200 grams.17 
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With such a large number of babies born to HIV infected mothers who have been on AZT 
PMCTC and a dearth of information on the effect of AZT on the low birth weight 
neonates, this study aimed to determine the prevalence and degree of anaemia in HIV-
exposed low birth weight neonates (< 2500g), admitted to the neonatal unit in King 
Edward VIII Hospital from April 2008 until February 2010, who were exposed to 
intrauterine AZT. 
Objectives 
1. To determine the prevalence of neonatal anaemia in low-birth weight, HIV-
exposed babies whose mothers  received AZT, at KingEdward Hospital 
2. To document the degree of and clinical significance of anaemia in HIV-exposed 
low birth weight neonates exposed to AZT 
3. To assess the correlation between duration of the maternal intake of AZT and 
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Methodology 
 
The researcher was solely responsible for data collection and extraction. 
Study design 
The study design was an observational, descriptive, and cross-sectional study.  
Study site 
The study site was the neonatal unit at King Edward VIII Hospital. This site was selected 
as there was a substantial number of HIV exposed low birth weight infants of whom full 
blood count results and duration of maternal AZT intake recorded which could be 
analysed. The total births in the study site, King Edward VIII Hospital, for 2009 was 
6802 including 1195 low-birth weight neonates.20  
 
Study population 
The study population consisted of all the low-birth weight (< 2500g) neonates whose 
mothers received AZT during gestation, admitted to the neonatal unit in King Edward 
VIII Hospital following which they attended the neonatal follow-up clinic for HIV-
exposed neonates from May 2008 to February 2010. The specified time frame was 
chosen because the new Department of Health PMTCT guidelines were implemented as 
of April 2008.  
Sample size calculations 
Based on an estimated prevalence of anaemia in HIV-exposed low birth weight babies 
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Selection of participants 
 
Participants were selected from the records of those who attended the neonatal fol ow up 
clinic for HIV-exposed neonates from May 2008 to February 2010 which was compiled 
by the paediatric department at the University of Kwazulu-Natal.21 This method of 
selection was chosen in conjunction with the paediatric department with the presumption 
that the mothers of the HIV-exposed neonates would have received AZT as per the new 
PMTCT national guidelines. The AZT registers were not used as they were often 
unreliable since they were inadequately entered in by the nursery staff. The low-birth 
weight babies were categorised according to gestation l age as follows: 
 
Gestational age:   26 - 28 weeks 
                         :    29 - 31 weeks 
                         : > 31 weeks 
                         
The neonates were divided into categories based on gestational age as the mean HB 





No sampling method was carried out as all 250 low birth weight HIV-exposed babies 
from the clinic database from April 2008 to February 2010 were used.21 A complete 
sample size is meant to improve precision of the study. 
 
However a reduced sample size of 95 of the 250 HIV-exposed low birth weight neonates 
with intrauterine exposure to AZT entered on the padi tric data base was used due to 
missing records, records not meeting the inclusion criteria, and after exclusion. The 
researcher had requested an extension of the original time period from April 2008 to 
11 
Dr S Hanley MMed Thesis 
December 2009, to April 2008 up until February 2010 in order to obtain more numbers. 




The inclusion criteria were HIV-exposed neonates who attended the neonatal follow-up 
clinic for HIV exposed babies at King Edward Hospital from May 2008 to February 
2010. 
 
• The neonates’ mothers must have received AZT during gestation 
• Birth weight less than 2500g 





Some of the other causes of neonatal anaemia (see literature review) were excluded to 
reduce compounding causes of anaemia. These were: 
 
• Acute maternal blood loss in the peri-partum period  
• Acute blood loss in the baby 
• Confirmed neonatal sepsis as per raised or low white blood cells, low platelets, 
elevated C-reactive protein and positive blood cultures. 
 
During the patient chart reviews of the complete sample, these factors were sought for in 
the history taking, examination findings and blood results and the babies who fulfilled 
these categories were excluded from the study.  
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Data source 
 
Using the information from the clinic database21 (which includes patient names, weight, 
hospital and contact numbers, and duration of intake of AZT by the mother), charts were 
located and reviewed for the following outcome variables: 
 
• Haemoglobin results at birth  
 
The exposure variables will consist of:  
 
• duration of AZT intake by the mother during gestation  
• weight of the baby  
• gestational age of the baby  
• gender of the baby 
 
To ensure internal validity in this descriptive study, FBC measurements carried out by the 
Sysmex XT2000i machine, calibrated every 2 months, serviced 6 monthly and control 
testing 4 times a day, were used in National Health Laboratory based at King Edward 
Hospital. 
  
Data collection method 
A recognised data collection tool is not a requisite as existing data will be used in contrast 
to the process of new data collection. A standard dta collection tool was used to collect 
the data from patients’ charts/records. 
 
The variables collected were the weights, gender and gestational age of the baby; 
haemoglobin results at birth; and the duration of maternal intake of AZT. See appendix 
for data collection sheet used by the researcher using Microsoft Word.   
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Data handling 
Data collection sheets were saved on the researcher’s PC secured with private password 
and backed-up at the University of Kwazulu-Natal Family Medicine department. Access 
was restricted to the researcher, supervisor and facilitator. The data will be secured for at 
least 5 years after the study.  
 
Data Analysis  
 
Data was captured and analysed using the SPSS software package. Prevalence of the 
anaemia (the outcome) was calculated using the total number of HIV-exposed infants 
with AZT exposure (the exposure) as well as the prevalence of anaemia in each 
gestational age category. The distribution of numerical data was graphically displayed 
using frequency distribution tables, bar graphs andbox and pie graphs. Independent T-
tests were used to demonstrate the relationship between the duration of AZT and the 
degree of anaemia. The numerical data was summarised by measures of central tendency 
i.e. mean and median, and by measures of variability i.e. range. 
 
Reliability, Validity and Bias 
Internal validity means that the study has measured what it set out to and strictly 
speaking, is the near truth about inferences regarding causal relationships which is not the 
intention of descriptive studies. To ensure internal validity in this descriptive study, FBC 
measurements carried out by the Sysmex XT2000i machine, calibrated every 2 months, 
serviced 6 monthly and control testing 4 times a day, were used in NHL lab King Edward 
Hospital. 
External validity: The study will be conducted and restricted to a single hospital which 
may not be generalized to other nursery settings in South Africa and possibly external 
validity may be affected. However being a regional hospital it is a referral institution of 
various clinics and hospitals from the greater Kwazulu-Natal province. 
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Reliability: The extent to which results are consistent over time and an accurate 
representation of the total population under study is referred to as reliability.  
 
Information bias: Information bias is inherent in chart reviews. Information regarding the 
neonate, for example examination findings and blood results, were often omitted in the 
medical records and added to information bias. A number of neonates who were found to 
have anaemia were diagnosed as sepsis based on elevated or low white cell counts, raised 
CRP and positive blood cultures. The researcher had devised a checklist and used this 
checklist in every chart review in order to exclude n onates who met the criteria for 
sepsis to minimize misclassification of sepsis. 
 
Selecting patients who attend the neonatal follow up clinic for HIV exposed infants result 
in selection bias. In order to minimize the bias, 100% (a complete sample) of the patients 
who attended the neonatal clinic for the determined time period were selected for chart 
review thereby eliminating sampling bias. However the small study size as a result of 
missing records may have significantly influenced the results. The confounders 
associated with low-birth weight neonates were addressed by exclusion of neonates who 
met criteria for the confounding factors. 
 
Ethical consideration 
Permission to conduct this study has been obtained from the University of Kwazulu-Natal 
Research Ethics Committee, King Edward VIII Hospital and the Kwazulu-Natal 
Department of Health, Natalia. Confidentiality of the study participants was ensured. 
Data collection sheets were saved on the researcher’s PC secured with private password. 
Access was restricted to the researcher, supervisor and facilitator. The data will be 
secured for at least 5 years after the study 
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Of the 250 records on the paediatric data base, 36%(90 patient files) could not be 
retrieved in the medical records department. 
 
From the 160 files located, 65 patient records did not meet the inclusion criteria and were 
not analysed due to the reasons outlined in Table 1. The predominant reason was that 
pregnant women did not receive AZT during gestation (34 /160, 21%) and therefore did 
not fulfil the inclusion criteria. Full blood count results were not available in 7.5% of the 
records, followed by 6.8% which were excluded because of maternal ante-partum 
haemorrhage and 6.2% which were excluded due to confirmed neonatal sepsis.  Other 
factors which resulted in a reduced sample size was th t 1.9% (3 women) of pregnant 
women were found to be on HAART and 0.6% of the reco ds had the diagnosis of acute 
haemorrhage in the baby. 
 
Table 1: Reasons for patient records not analysed 
Reason for files not analysed Number of files 
Pregnant women did not receive AZT  34  (7 confirmed unbooked pregnancies) 
No blood results 12 
Ante-partum haemorrhage 11 
Neonatal sepsis 10 
Neonatal pulmonary haemorrhage 1 
Maternal HAART 3 
 
Three mothers who were diagnosed with ante-partum haemorrhage did not receive 
PMTCT AZT as well, and three babies diagnosed with neonatal sepsis were born to 
mothers who did not receive AZT. Therefore they each ppeared twice in the above table. 
16 






Figure 1: Gender Distribution of Study Neonates as a Percentag  
 
Figure 1 illustrates the gender distribution of the95 neonates analysed in the study. There 
were more males which constituted 58% (55/95) of the total sample size. There were 40 

















Figure 2: Neonatal Gestational Age Distribution in Weeks 
 
The neonatal gestational age was categorised into three groups, 26-28 weeks, 29-31 
weeks and over 31 weeks of age. Of these, the majority (66%) of neonates fell into the 
over 31 week gestational age category, followed by the 29-31 week category of 28% (N-
95). The minority of neonates fell into the 26-28 weeks category (6%) of the total number 
of neonates (Figure 2). Table 2 below displays the descriptive statistics for gestation l 
age. Since the age was not normally distributed as shown by the Shapiro-Wilk test for 
normality, a better representation of the central tendency was the median instead of the 




Table 2: Descriptive statistics for Neonatal Gestational Age 
 Statistic 
Median 32.00 
 Minimum  26.00 
 Maximum  38.00 
Range 12.00 
Age in weeks 
Interquartile Range 5.00 
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Figure 3: Distribution of Neonatal Weight as a percentage 
 
This study population consisted of low birth-weight neonates weighing less than 
2500grams. The majority of neonates weighed between 1501 to 1700grams (17.9% of 
N=95, see figure 3). The neonates were then equally distributed into the 1101-1300 
grams, 1301-1500 grams, and 1701-1900 grams categories (15.8% each). The least 
number of neonates weighed between 701-900 grams (3.2%). Table 3 shows the 
descriptive statistics for the neonatal weight. As weight was normally distributed, the 
mean value was calculated. The mean neonatal birth weight was 1610.92g which was 
only 10g closer to the minimum weight when comparing the value obtained by addition 
of the minimum and maximum weights and dividing by 2. Under the 95% CI, the 
estimated mean for the target population was 1529.27 – 1692.55g. The range was high for 
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Table 3:  Descriptive statistics for Neonatal Weight 
Mean 1610.92 
Lower Bound 1529.27 95% Confidence Interval for 
Mean (CI) Upper Bound 1692.55 
Std. Deviation 400.75 
Minimum 750.00 































Figure 4: Mean Haemoglobin by Gestational Age in g/dL 
 
According to recent literature the normal mean haemoglobin in neonates aged 26-28 
weeks is 15.1g/dL; aged 29-31 week category is 16.2g/dL and 19.3 g/dL in the age group 
above 31 weeks.16 Figure 4 shows results of the calculated mean Hb in the different age 
groups. The mean Hb was 17g/dL in the 26-28 week category, 16 g/dL in the 29-31 week 
category and 17 g/dL in the over 31 week category. These findings are evaluated further 
in the discussion.  
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Table 4:  Distribution of Neonatal Haemoglobin in g/dL 
Mean 16.65 
Lower Bound 16.08 95% Confidence Interval for 
Mean Upper Bound 17.22 






























Figure 5: Prevalence of Neonatal Anaemia according to Gestation l Age 
 
Figure 5 demonstrates the prevalence of neonatal anaemia in the specified gestational age 
categories using the definition of anaemia given. In the gestational age category of 26-28 
weeks, 1 out 6 neonates (16.7%) had anaemia (HB < 13.5g/dL). In the gestational age 
category of 29-31 weeks, 10 out of 27 neonates (37%) had anaemia (HB < 14.5g/dL). 
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The highest prevalence of anaemia (54.8%) was found in the gestational age category 






















Haemoglobin (AZT < 28 days) Haemoglobin (AZT > 28 days)
 
Figure 6: Distribution of haemoglobin in neonates at birth exposed to AZT for less than 
and more than 28 days in the 26-28 week gestational age category. 
 
There were a total of 6 neonates in the 26-28 week g stational age category. Five 
neonates were in the AZT less than 28 day group and only 1 neonate had more than 28 
days of AZT exposure. Figure 6 illustrates the distribu ion of neonatal haemoglobin in 
neonates with less than and more than 28 days of AZT exposure in this age category.  
The mean haemoglobin in neonates with less than 28 days of AZT exposure was 
16.78g/dL and for those with greater than 28 days exposure was 18.1g/dL. The study 
found that the difference in Hb was statistically insignificant when comparing the 






















Haemoglobin (AZT < 28 days) Haemoglobin (AZT > 28 days)
  
 
Figure 7: Distribution of haemoglobin in neonates at birth exposed to AZT for less than 
and more than 28 days in the 29-31 week gestational age category.  
 
Twenty seven neonates were in the 29-31 week gestational age group. Nineteen neonates 
were in the AZT less than 28 day group and 8 neonats had more than 28 days of AZT 
exposure. Figure 7 shows the distribution of neonatal haemoglobin in neonates with less 
than and more than 28 days of AZT exposure in this age category.  
The mean haemoglobin in neonates with less than 28 days of AZT exposure was 
16.37g/dL and for those with greater than 28 days of exposure to AZT was 13.65g/dL. 
There was a statistically significant lower mean  Hb  in the neonates exposed to more 
than 28 days of AZT in the above age group (p value=0.021).  
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Figure 8: Distribution of haemoglobin in neonates at birth exposed to AZT for less than 
and more than 28 days in the over 31 week gestational age category. 
 
There were a total of 62 neonates in the over 31 week gestational age category. Twenty 
eight neonates fell into the AZT less than 28 day group and 34 neonates had more than 28 
days of AZT exposure. Figure 8 illustrates the distribu ion of neonatal haemoglobin in 
neonates with less than and more than 28 days of AZT exposure in this age category.  
The mean haemoglobin in neonates with less than 28 days of AZT exposure was 
17.42g/dL and for those with greater than 28 days of exposure to AZT was 16.81g/dL. 
There was no statistical significance in difference in neonatal Hb in the two AZT duration 
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Table 5: Descriptive statistics for maternal AZT 





<28days 26 26 52 
Maternal AZT 
>28days 14 29 43 
Total 40 55 95 
 
Table 5 describes the overall statistics for maternl AZT duration in males and females. 
 
Table 6:  Pearson’s correlation between neonatal weight and HB 
 HBg/dl @birth 
Pearson Correlation 0.041 
Sig. (2-tailed) 0.694 Weight grams 
N 95 
Correlation is significant at the 0.05 level (2-tailed). 
 
Table 6 is the Pearson’s correlation test for neonatal weight and haemoglobin. This shows 
a very low and insignificant correlation value of 0.041 and a p value of 0.694 between 
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Table 7:  Spearman’s correlation between neonatal weight, HB and gestational age 
 weight grams HBg/dl @birth age wks 
Correlation Coefficient 1.000 0.065 0.701**  
Sig. (2-tailed) . 0.530 0.000 weight grams 
N 95 95 95 
Correlation Coefficient 0.065 1.000 0.263* 
Sig. (2-tailed) 0.530 . 0.010 HBg/dl @birth 
N 95 95 95 
Correlation Coefficient 0.701**  0.263* 1.000 
Sig. (2-tailed) 0.000 0.010 . 
Spearman's rho 
age wks 
N 95 95 95 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
 
Table 7 displays the correlation between neonatal weight, haemoglobin and gestational 
age.  The correlation between neonatal Hb and gestational age was statistically significant 
with a p value of 0.01. There was no statistical signif cance between Hb and weight. 
 
 
Table 8: Descriptive Statistics for Gestational Age and Maternal AZT 
Intake 
 maternal AZT N Mean Std. Deviation Std. Error 
Mean 
<28days 52 31.7115 2.46017 .34116 age wks 
>28days 43 33.6512 2.51551 .38361 
 
 
The mean gestational age in the group with less than 28 days of AZT was 31.71 weeks 
and the mean gestational age in the over 28 day category was 33.65weeks (Table 8). A t-
test was carried out between gestational age and duration of AZT intake. The correlation 
was found to be statistically significant (p value-0.01). 
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Discussion: 
  
One hundred and sixty files were located out of the 250 records on the paediatric 
database. A total of 95 neonatal birth records fulfilled the inclusion criteria and were 
analysed. This resulted in a small study size and the findings of this study are therefore 
not generalizable.  
 
The small study size was largely contributed to a significant number of missing records 
and misplaced blood results. Poor record keeping and loss of data is a significant 
weakness inherent in retrospective studies. Despite the paediatric department having a 
complete database, at least 36% of the records weremissing in the medical records 
department. This was a major flaw in the study and beyond the researcher’s control. 
Evaluation of records is an important part of audit used to promote improved quality of 
care, and of research.22 Without good record keeping systems in place neither of these 
can place. 
 
Another important reason for the reduced study size was because a substantial number of 
mothers (34/160, 21%) on the paediatric data base for HIV-exposed babies had not been 
commenced on PMTCT medication for various reasons. Some of the reasons for the 
women not receiving AZT included the fact that the study start date was April 2008 when 
the new national PMTCT guidelines were only just introduced and many clinics had not 
yet implemented the national guidelines. This demonstrates a delay in the PMTCT 
programme being put into practice and is one of the c allenges of implementing new 
policies. Approximately 350 000 babies became infected with HIV in 2007.23An 
estimated one third of HIV positive pregnant women r ceived PMTCT in 2007.24This 
emphasizes the lack of implementation of PMTCT in many resource limited settings. The 
fact that 34 women attended at least one antenatal visit and were not started on 
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A further reason for PMTCT not being taken was that a number of pregnant women 
presented for the first time in labour and were un-booked at antenatal clinics (however 
only 7 un-booked could be confirmed for certain). For these women, HIV testing was 
only performed intra-partum and often post-partum and t the very most a stat dose of 
Nevirapine was administered to the pregnant women intra-partum reducing the efficacy 
of PMTCT intervention.  
 
Contributing to the small number were neonates excluded due to the diagnosis of sepsis 
(10 neonates), as well as neonates of mothers with ante-partum haemorrhage (11 
neonates). One neonate was excluded as a result of pulmonary haemorrhage. These 
records were excluded as the neonates were exposed to potential confounding factors that 
could affect the haemoglobin value. Neonates of mothers who were on HAART (triple 
ARV therapy) were also not included and therefore neonates of mothers with possibly 
low CD4 counts were not analysed and in-utero side effects of HAART on the baby was 
not evaluated. Currently the focus of research has moved towards assessing the efficacy 
and side effect profile of triple ARV prophylaxis compared to dual PMTCT therapy on 
mother and baby. 2 
 
The demographic representation of the study neonates was described beginning with 
gender of the neonates. There was a male predominance of 58% versus females of 42%.  
 
Thereafter the neonatal gestational age was describd in Figure 2. The neonates were 
categorised into different age groups corresponding to the three grades of preterm births. 
Extremely preterm babies are babies born earlier than 28 weeks gestation, very preterm 
babies are born between 28 - <32 weeks gestation and moderate to late preterm babies are 
born from 32 - <37 weeks gestation.24 In this study the majority of neonates fell into the 
>31 week gestational age category whereas the minority were aged between 26 – 28 
weeks gestation. This is in keeping with Blencave et al25 who demonstrated that the 
number of babies born increases as the gestational age increases. The median neonatal 
gestational age was 32 weeks (Table 2). The youngest babies were born at 26 weeks 
gestation. The maximum gestational age of 38 weeks exceeded the cut of for the 
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definition of preterm birth however the babies born at this gestation were still low birth 
weight babies weighing less than 2500g. The gestation l age was skewed towards the 
maximum gestational age of the study neonates and all the ages were closely clustered 
with a small interquartile range as one would expect to find for gestational age. This 
distribution of gestational age allowed for the objectives of the study to be answered.  
 
The study looked at low birth weight neonates only. The majority of babies (17.9%) 
weighed between 1501 - 1700grams followed closely by babies who weighed 1101-
1500g (15.8% in each) and 1701-1900g (15.8%, see Figure 3). Only 11.6% of neonates 
were extremely low birth weight (<1000g) but this was anticipated as there are fewer 
babies in this weight category who are delivered.24 There was a total percentage of 43.2% 
who were very low birth weight babies (<1500g). Table 3 shows the minimum birth 
weight was 750g and the maximum weight was 2490g. The mean neonatal birth weight 
was 1610.92g which was only 10g closer to the minimum weight when comparing the 
value obtained by addition of the minimum and maximum weights and dividing by 2. The 
distance between the mean neonatal weights and all other weights, as depicted by the 
standard deviation, was high.   
 
The mean neonatal haemoglobin was calculated in the thre  gestational age groups as 
the haemoglobin is shown to increase with gestationl age in premature babies. It was 
remarkable to note that local national laboratory reference ranges for normal 
haemoglobin levels at birth and other full blood count parameters are currently 
available for full-term babies only. The normal reference ranges for preterm neonates 
were obtained from a 2011 text book of neonatal andperi-natal medicine written 
based on international standards15 and therefore based on mean haemoglobin values 
of neonates outside our local setting. When directly comparing the calculated mean in 
this study to the normal values for mean Hb in each age group, as well as comparing 
the study mean to the normal value for mean Hb minus 2 standard deviation below 
the mean Hb (see definition of anaemia on page 6), it was noted that the calculated 
study mean Hb of 17g/dl was greater than the normal ean Hb of 15.1g/dL and 
greater than the mean minus 2SD of 13.5g/dL. The calculated mean Hb in the 29-31 
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age group was 16g/dL and this was lower than the known mean Hb value of 16.2g/dL 
but higher than the mean minus 2SD of 14.5g/dL. In the >31 week gestational age 
group the calculated mean of 17g/dL was less than te mean of 19.3g/dL and less 
than the mean minus 2SD of 17.1g/dL. Therefore the mean neonatal Hb in the study 
neonates exposed to AZT were lower compared to the normal values for neonatal Hb 
at birth.  
 
Table 4 displays a minimum haemoglobin of 11.0g/dL and maximum haemoglobin of 
24g/dL. As anaemia is said to be clinically significant and severe when the haemoglobin 
is less than 10g/dL during the first few days of life (Grade 3, Grade 4 Division of AIDS 
toxicity levels)19, none of the neonates included in this study had a severe anaemia at 
birth. These findings are similar to large international randomised double-blinded 
placebo-controlled studies, Connor et al4 nd Sperling10 et al, who demonstrated a mild 
and transient anaemia in term newborn babies exposed t  intrauterine AZT. The African 
study by Ziske et al13 also showed similar mild haematological side effects on the 
newborn with in-utero AZT exposure. The anaemia in a newborn can be graded in 
accordance with the DAIDS toxicity table into a Grade 1 Hb from 12g/dL-13g/dL and 
Grade 2 from Hb 10g/dL-11.9g/dL. However these values apply to full-term infants only 
and it is recommended by DAIDS that local normal refer nce ranges be applied when 
grading anaemia in pre-term infants. There are no locally available reference ranges and 
grading systems and therefore the anaemia could not be graded. For the purposes of the 
second study objective which was to document the degree of anaemia in HIV-exposed 
low birth weight neonates exposed to AZT, the degre of neonatal anaemia is said to be 
clinically insignificant (Hb>10g/dL) or clinically significant (Hb>10g/dL).19 In this study 
neonatal anaemia was found to be clinically insignif cant as all Hb values were greater 
than 10g/dL. 
 
The total prevalence of neonatal anaemia in low-birth weight, HIV-exposed babies 
whose mothers have been receiving AZT, at King Edwar  Hospital from April 2008 
to February 2010 was 47% across all gestational age groups. The neonates were then 
placed into categories according to gestational age. Th  prevalence in the 26-28 week 
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gestational age category was 16.7%, in the 29-31 week category the prevalence was 
37%, and in the over 31 week gestational age category the prevalence was 54.8%. 
(Figure 5) The high prevalence of neonatal anaemia in the study is in keeping with the 
commonly known side effect of AZT described in the above mentioned randomized 
control trials as well as a Cochrane meta-analysis by Volmink et al.7 A Tanzanian 
study demonstrated an overall rate of 29% for a Grade 1 anaemia in full-term infants 
who had intrauterine AZT exposure.13 The prevalence of anaemia was shown to 
increase with gestational age and these findings could indirectly address the 3rd 
objective in the study.  There was a statistically significant correlation between 
gestational age and duration of AZT intake (p value of 0.01) indicating that the 
pregnant women may have taken AZT for a greater duration when continuing to a 
later gestation and subsequently caused a higher prevalence of anaemia in the later 
gestation. However the numbers in this study are small and all results must be treated 
with caution. No other studies were carried out comparing gestational age groups in 
preterm and low birth weight babies therefore it isnot possible to compare the study’s 
findings to what is already known. It is worthwhile to reiterate that the normal values 
for mean neonatal Hb at birth was taken from recent literature based on findings in a 
first-world setting. These normal values may be higher than what is normal for a 
South African newborn Hb. We have calculated the prevalence of anaemia based on 
the differences between South African newborns’ Hb values and the Hb values of 
babies born into a first world country and therefor the prevalence of anaemia may be 
exaggerated in this study. 
 
The third objective of the study was to assess the correlation between duration of the 
maternal intake of AZT and severity of neonatal anaemi . This is worthwhile in doing in 
light of the latest PMTCT guidelines that require pr gnant women to receive AZT at an 
earlier gestation of 14 weeks as it was found that t e longer the exposure to PMTCT the 
lower the transmission rates of the HI virus to the fo tus and neonate. In the 26-28 week 
gestational age category, the majority of babies were exposed to a shorter duration of 
AZT (Figure 6). Only one neonate in this category was exposed to greater than 28 days of 
AZT. The mean Hb was greater in the AZT>28 day group, however this is not significant 
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as there was only one Hb value in that group. There was no significance between Hb and 
duration of AZT exposure (p value of 0.609). A local study showed that majority of 
South African pregnant women had booked at a late gestation for the initial antenatal 
visit. These findings suggest that pregnant women who present in preterm labour may 
have taken AZT for a relatively short period of time.26 
 
In the 29-31 week gestational age category majority f the neonates were exposed to 
less than 28 days of AZT (76%, see Figure 7). The mean neonatal Hb was lower in 
the neonates exposed to longer duration of AZT. (13.63g/dL vs 16.37g/dL) and there 
was a statistically significant correlation between the neonatal Hb and duration of 
AZT in this age category. (p value 0.02)  
 
In the over 31 week gestational age category 45% of the babies were exposed to less than 
28 days of AZT and 55% were exposed to more than 28 days of AZT (figure 8). The 
mean Hb in neonates with less than 28 days of AZT exposure was higher (17.42g/dL) 
than the mean Hb in the group with the lower duration of AZT (16.81g/dL). There was no 
statistical significance shown when assessing correlation between neonatal Hb and AZT 
duration. (p value 0.38) 
 
Although there appears to be a correlation between AZT duration and neonatal Hb in 
the middle age group, the degree of anaemia was still no  severe. Table 4 shows an 
equal number of male and female neonates were exposd t  less than 28 days of AZT 
in-utero and more females than males were exposed to more than 28 days of AZT. 
The risk of clinically significant anaemia was not associated with the duration of 
maternal AZT intake demonstrated in a study assessing the safety of maternal infant 
AZT regimen used in the PACT 076G study.10 These findings are however different 
to another similar study by Lallemant et al that looked at a long and short arm of 
maternal intake of AZT and the side effects of each on mother and baby. The study 
showed that mothers who were exposed to the longer AZT treatment arms 
experienced more neonatal complications, for example neonatal anaemia, and other 
obstetric events.27  Further research is required to adequately assess th  correlation 
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between AZT duration and degree of neonatal anaemia at birth. For now the benefits 
of AZT PMTCT commenced at an earlier gestation outweigh the overall risks. 
 
The other exposure variables were compared to the neonatal haemoglobin. The 
Pearson’s correlation between neonatal weight and Hb was not significant (p value of 
0.694, see Table 6). Neonatal Hb was shown to increase with gestational age. (p value 
of 0.01) and this finding further highlights the need for assessing neonatal Hb in the 
different age groups. As one would normally expect, the correlation between neonatal 
age and weight was demonstrated to be significant (Table 7). 
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Limitations: 
The following limiting factors were taken into consideration throughout the study: 
 
• This study is entirely descriptive. Only temporal relationships were demonstrated 
and no causal association could be concluded.  
• The inability to find all the records and the resultant small study size may have 
biased and significantly influenced the results. 
• A number of neonates who were found to have anaemia were diagnosed as sepsis 
based on elevated or low white cell counts, raised CRP and positive blood 
cultures. However some of the neonates who were classified as sepsis did not 
have these confirmatory results and were treated as sep is based on other clinical 
findings.  In other words the diagnosis of sepsis was not clear. These patients 
were all excluded from the study however the clinical findings could have 
possibly been related to in - utero AZT toxicity 
Confounders: 
 
The study population itself is a major confounder because anaemia is a result of 
prematurity. The other confounders were:  
 
• Sepsis 
• Acute blood loss in the mother peri-partum                excluded from the study 
• Acute blood loss in the baby 
• Haemolytic disease of the newborn 
• Recurrent phlebotomy 
 
In a descriptive study which is not set out to infer causal relationships, it was not 
imperative to consider every one of these confounders. 
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The prevalence of neonatal anaemia in low-birth weight, HIV-exposed babies whose 
mothers have been receiving zidovudine, at King Edwar  Hospital from April 2008 to 
February 2010 was high, which is in keeping with the commonly known side effect of 
AZT demonstrated in large randomized controlled studies and a systemic reviews 
worldwide including Africa. The haematological side effects of anaemia in neonates 
resulting from AZT exposure in-utero were found to be of a mild and clinically 
insignificant nature in keeping with existing studies. The degree of neonatal anaemia in 
low birth weight/ pre-term neonates appears to be the same as in full-term neonates of 
normal birth weight depicted in the majority of studies. The presence of neonatal anaemia 
at birth has been shown to be related to the duration of exposure to intrauterine AZT in 
only one of the three age groups assessed, and the anaemia is clinically mild. There were 
no identified issues that would warrant amending current recommendations for the 
routine use of AZT for the prevention of mother-child HIV transmission however these 
findings require further research involving larger numbers and follow up of neonates in 
order to adequately analyse current PMTCT guidelines.  
 
Recommendations: 
Further research would be required to confirm the results of the study in view of the small 
sample size and lack of generalizability. The ongoi PROMISE IMPAACT clinical trial 
will demonstrate side effects of all PMTCT medications determined on a larger scale and 
will also shed more light on the duration of exposure to AZT on neonatal anaemia. 
 
The investigator believes it will be helpful to perform research in order to assess current 
adherence to PMTCT national guidelines at the local primary health care clinics 
responsible for rendering these services. 
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